Company intelligence / Profile preview

江苏大红鹰恒顺药业

Shuyang, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

江苏大红鹰恒顺药业为多产品生产型医药公司，核心业务为大输液、注射剂等药物的商业化生产，获批产品包括小容量注射剂（如门冬氨酸洛美沙星注射液），面向国内及海外市场销售。

Therapeutic areas: OncologyCardiovascularOther
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Nanjing Hengdao Pharmaceutical TechnologyJiangsu Hengshun GroupPharmaceutical research institutes in Beijing, Shanghai, Nanjing, Wuhan, Hangzhou, Ningbo

Beyond the preview

Go deeper on 江苏大红鹰恒顺药业.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 江苏大红鹰恒顺药业.

Explore the full profile